Love's Affairs, Heart's Affairs

It seems to be quite right what ancient believers used to say about the place where love is placed. As matter of fact, accordding to a University of Pennsylvania's reasearch, making love at least twice a week, can reduce heart disease in men by half, study reveals

Read more in the Daily Mail By Pat Hagan

Men don't usually need an excuse to indulge in a spot of passion.
But if they did, here's one that sounds more convincing than most - making love is good for their hearts, it seems.
Men who have sex at least twice a week can almost halve their risk of heart disease, according to research.

Healthy love life: Sex twice a week can reduce the risk of heart disease in men
Those who make love regularly are apparently up to 45 per cent less likely to develop life-threatening heart conditions than men whose sexual encounters are limited to just once a month or less.
The study, of more than 1,000 men, shows sex appears to have a protective effect on the male heart but did not examine whether women benefit too.
Now the American researchers are calling for doctors to 'screen' men for sexual activity when assessing their risk of heart disease.
The benefits of love-making could be due to both the physical and emotional effects on the body, they said.

'Men with the desire for frequent sexual activity and who are able to engage in it are likely to be healthier,' the scientists told the American Journal of Cardiology.
'But sex in some forms has a physical activity component that might directly serve to protect cardiovascular health.
'Also, men who have frequent sex might be more likely to be in a supportive intimate relationship.
'This might improve health through stress reduction and social support.'
The scientists at the New England Research Institute, based in Massachusetts, spent 16 years tracking the sexual activity of men aged between 40 and 70.
Each of the volunteers was quizzed at regular intervals about how often they had sex.
They were then checked for signs of heart disease. Other risk factors, such as age, weight, blood pressure and cholesterol levels, were also taken into account.
Although sex has long been regarded as good for both physical and mental health, there has been little scientific evidence of benefits on major illnesses such as heart disease until now.
An earlier study at the National Cancer Institute in the U.S. showed men who ejaculated through sex or masturbation at least five times a week are much less likely to develop prostate cancer.
And having sex once or twice a week during the winter months can boost the immune system and reduce the chances of catching colds and flu, according to scientists at Wilkes University, Pennsylvania.
It boosts levels of a chemical called immunoglobulin A 6, which binds to organisms that invade the body and then activates the immune system to destroy them.
Regular intercourse can even boost a woman's sense of smell by triggering the release of a hormone called prolactin, researchers at Canada's Calgary University found.
This may be a mechanism to help mothers bond with their new babies.
Every year, around 270,000 people in Britain suffer a heart attack, and coronary disease remains the nation's biggest killer.Read more: http://www.dailymail.co.uk/news/article-1241692/Having-sex-twice-week-reduce-heart-disease-men-half-study-reveals.html#ixzz0cBbw5tIl

Distrusting easy weightbust

If you want to bust your exceeding weight it's better start moving up, training or taking some advice from your own doctor. Taking pills for easy bustweight, according to a research by the EMA, can highly increase the risk on developping heart problems. It seems that Sibutramine, marketed in Great Britain as Reductil and in the USA as Meridia, raising blood pressure, can even lead to heart attack.

Read more

Heart attack and stroke fears over fat-busting wonder pill
By Jo MacfarlaneLast updated at 8:02 AM on 03rd January 2010

Overweight people who have been using Reductil could be more at risk of heart attacks and strokes
A fat-busting pill used by thousands in the UK is being investigated by medicines watchdogs over fears it could cause heart attacks and strokes.
The European Medicines Agency (EMA), which licenses the use of the drug Reductil, is looking at the results of a clinical trial which suggests that its active ingredient, sibutramine, could lead to an increased risk of developing heart problems.
Nearly 330,000 prescriptions for the drug, which tricks the brain into believing the stomach is full, were written out in 2008.
The safety data has come from an international trial of 10,000 patients carried out during the past six years.
Most of those recruited for the Sibutramine Cardiovascular Outcome Trial (SCOUT) were overweight or obese and already had cardiovascular problems.
A heart condition would normally exclude them from taking the drug because it can slightly raise blood pressure.
However, the EMA has said that, as a result of the ‘seriousness’ of the study’s concerns, it is looking at the implications for all patients offered the prescription-only drug and will release its findings later this month.
Until then, it has advised doctors to use Reductil ‘with caution’ and to monitor patients’ blood pressure and heart rate.
The UK’s medicines watchdog, The Medicines and Healthcare Products Regulatory Agency, also confirmed it was reviewing the data.

The agency has recorded 2,094 suspected adverse reactions to Reductil since it was introduced in 2001, and 17 deaths have been linked to the drug. Six of the deaths were caused by heart problems and strokes.
Reductil works by blocking the nerve cells that release and reabsorb the hormone serotonin, a chemical neurotransmitter in the brain that affects moods and appetite.
As the level of serotonin in the body rises, people feel fuller, eat less and, as a result, lose weight.
The drug is recommended for patients who are clinically ‘obese’ – those with a Body Mass Index over 30 – or for anyone with a BMI higher than 27 who has another weight-related health problem.
A spokesman for Abbott Laboratories, which manufacturers Reductil, said: ‘Our ongoing evaluation of the SCOUT study data does not change our medical assessment of sibutramine’s risk/benefit profile when used appropriately in the approved patient population.
'Sibutramine is an important treatment for patients who are obese.Read more: http://www.dailymail.co.uk/health/article-1240147/Heart-attack-stroke-fears-fat-busting-wonder-pill.html#ixzz0bXZ1mFJp